SA

Sanofi

Every trial this sponsor leads in the registry, and everything it has published.

2,208All trials
Recruiting69
Recruited76
Not yet recruiting7
By invitation5
Completed1,781
Stopped266
Other4

157 active · 7% of this sponsor’s registry footprint

Immunology & Inflammation27 trials
Infectious Disease23 trials
Dermatology20 trials
Respiratory14 trials
Metabolic/Endocrine/Nutrition12 trials
Oncology12 trials
Haematology10 trials
Neurology9 trials

Not shown above: 3 Phase 1 healthy-volunteer trials and 18 trials whose condition matched no therapy area.

Trials by phase

Phase 1456
Phase 2540
Phase 3778
Phase 4386
Unphased48

Pipeline by phase · 53 drugs in active development

Phase 3 · 15 drugs

Rilzabrutinib8 trials · 5 recruitingest. Nov 2026
Isatuximab7 trials · 2 recruitingest. Jan 2027
Amlitelimab6 trialsest. Sept 2026
Frexalimab6 trials · 3 recruitingest. Dec 2026
Lunsekimig6 trials · 2 recruitingest. Jun 2027
Duvakitug5 trials · 4 recruitingest. May 2028
PCV21 vaccine5 trials · 1 recruitingest. May 2027
Itepekimab4 trialsest. Oct 2026

Phase 2 · 14 drugs

Brivekimig (SAR442970)4 trials · 3 recruitingest. Dec 2026
Balinatunfib (SAR441566)3 trialsest. Sept 2026
SAR441344 IV2 trials
SAR4458772 trials · 2 recruitingest. Jan 2027
BLU-8081 trialest. Dec 2026
Eclitasertib (SAR443122)1 trial

Phase 1 · 14 drugs

Acne mRNA vaccine2 trials · 2 recruitingest. Nov 2028
SAR4485012 trials · 2 recruitingest. Jan 2028
Chlamydia mRNA Vaccine1 trial · 1 recruitingest. Jan 2028
H5 Flu Investigational Medical Product (IMP) 11 trial · 1 recruitingest. Apr 2027
SAR4026631 trialest. May 2027

Phase 4 · 10 drugs

Dupilumab20 trials · 8 recruitingest. Sept 2026
Belumosudil6 trials · 2 recruitingest. Sept 2026
Avalglucosidase Alfa4 trials · 1 recruitingest. Jun 2027
Fitusiran4 trials · 2 recruitingest. Nov 2026
teplizumab3 trials · 2 recruitingest. Mar 2028
avapritinib2 trials · 1 recruitingest. Jun 2027
Efanesoctocog alfa2 trials · 1 recruitingest. Jan 2027
iGlarLixi (insulin glargine/lixisenatide)1 trial · 1 recruitingest. Sept 2026

Not counted above: 1 unphased intervention.

Active trials only, code names and brands merged. 1,781 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 5 of 10 curated

Atopic dermatitis (Dermatology)11 trials · 3 recruiting · 2 drugs6.3% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)6 trials · 3 recruiting · 5 drugs3.6% of landscape
Multiple myeloma (Oncology)4 trials · 1 drug0.5% of landscape
Alzheimer's disease (Neurology)1 trial · 1 recruiting0.3% of landscape
Type 2 diabetes (Endocrinology)1 trial · 1 recruiting · 1 drug0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon